12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ACH-3102: Phase I data

A Phase I drug-drug interaction study in 24 healthy volunteers showed there was no interaction between sovaprevir and ACH-3102. The combination was well tolerated with no significant adverse events reported. Data were presented at the American...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >